Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

News SummaryMost relevantAll newsSector newsTweets 

Merck KGaA Gives Details On Planned Efficiency Program

share with twitter share with LinkedIn share with facebook
share via e-mail
02/24/2012 | 05:51pm CET

-- Germany's Merck provides details about efficiency program.

-- Conglomerate joins a long list of drug makers revamping themselves.

-- Merck KGaA shares fall after restructuring update.

(Adds details, share details, background.)

   By Neetha Mahadevan 

Pharmaceutical and chemical company Merck KGaA (>> Merck KGaA) said Friday it launched a cost-cutting and efficiency plan in the wake of increased price pressures in the U.S. and Europe and a series of drug development setbacks.

The company said the plan could involve job cuts across all businesses and regions to reduce costs and address "unprecedented market shifts", but it didn't disclose details, saying management still needed to speak with relevant stakeholders for a mutually acceptable solution.

"Over the next two years, Merck needs to address unprecedented market shifts, increasing competition in key product areas and existing inefficiencies in its own organization to ensure the long-term success of its business model," Chief Executive Karl-Ludwig Kley said in a statement.

With its new cost-cutting drive, the German chemical and pharmaceutical company joins a long list of other drug makers who are revamping themselves in response to falling sales and profitability.

The need to cut costs is partly due to mounting pressure stemming from health care reforms in the U.S. and Europe, where governments are increasingly reluctant to reimburse expensive drugs and advocate the use of cheaper generic medicines. Companies such as AstraZeneca Plc (AZ.LN), Novartis AG (NVS), Roche Holding AG (ROG.VX), Pfizer Inc (>> Pfizer Inc.), Eli Lilly & Co (>> Eli Lilly & Co.) have all embarked on cost saving or restructuring programs to keep costs under control.

In addition to set-backs in its drug pipeline, Merck has also been hit by a slowdown in demand at its chemicals division, which led to disappointing developments in the last year and prompted it to tighten its outlook time and again.

In the second-quarter, it recorded a 6.5% drop in revenue at its chemicals division, while in the third-quarter profits fell due largely to weakness in its performance materials division.

The efficiency measures are part of Merck's comprehensive transformation program, announced last year, and comprises two phases, the company said.

In the first two years, Merck plans to set up a new leadership organization, implement efficiency measures and focus on long-term growth, while the second phase will be focused on exploiting new growth opportunities, it added.

Merck KGaA shares fell after the news and at 1545 GMT traded down 1.2% at EUR79.70, while the DAX benchmark index traded 0.6% higher.

-By Neetha Mahadevan, Dow Jones Newswires; +49 69 2972 5507; neetha.mahadevan@dowjones.com

(Sten Stovall contributed to this article.)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK KGAA
02/24 MERCK : Researchers from Merck KGaA Detail Findings in Robotics [Development of ..
02/24 MERCK : Receives Positive CHMP Opinion for New Pergoveris® Fertility Pen
02/16 MERCK : New Hypertension Findings from Merck KGaA Described [Management of Hyper..
02/16 MERCK : North American Businesses of Merck KGaA, Darmstadt, Germany Certified as..
02/15 MERCK : to Supply Single-Use Systems to WuXi Biologics for Non-GMP Pilot Plant i..
02/09 Verastem Announces Dosing of First Patient in Combination Trial of Defactinib..
02/09 MERCK : North American Businesses of Merck KGaA, Darmstadt, Germany Certified as..
02/09 MERCK : Cladribine Tablets Significantly Reduced Brain Atrophy in Patients with ..
02/07 MERCK : Jaffrey biochemical company to pay fine by EPA after alleged water pollu..
02/07 MERCK : Millipore settles lawsuit with EPA
More news
Sector news : Specialty & Advanced Pharmaceuticals
06:13p FTSE ends higher on some positive earnings, insurers slip
08:06aDJSANOFI : Lonza to Invest CHF290 Million in New Plant in Switzerland
02/24DJSHIRE : Files 8K - Other Events
02/24DJASTRAZENECA : Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
02/24DJASTRAZENECA : Gets Approval for Drug Treating Hyperkalaemia
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
07:38a Roche's Renal Success Spells Danger For All-Comer Studies
02/03 Pfizer May Be Another IBM
01/23 Merck KGaA teams up with Domain Therapeutics in immuno-oncology
01/18 Astra's Mystic Mystery And Other Surprises In Store
01/12 Vertex And German Merck Find Their Perfect Fit
Financials (€)
Sales 2016 15 060 M
EBIT 2016 3 447 M
Net income 2016 1 795 M
Debt 2016 11 019 M
Yield 2016 1,19%
P/E ratio 2016 24,34
P/E ratio 2017 23,23
EV / Sales 2016 1,62x
EV / Sales 2017 1,44x
Capitalization 13 338 M
More Financials
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 109 €
Spread / Average Target 5,7%
Consensus details
EPS Revisions
More Estimates Revisions
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA4.08%14 073
ABBVIE INC-0.85%98 967
More Results